The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Open accessAbstract
Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses have emerged as a major problem that is observed in approximately 30% of treated patients. Developing approaches to preventing and treating antigen-loss escapes would therefore represent a vertical advance in the field. Here, we found that in primary patient samples, the IL-3 receptor α chain CD123 was highly expressed on leukemia-initiating cells and CD19-negative blasts in bulk B-ALL at baseline and at relapse after CART19 administration. Using intravital imaging in an antigen-loss CD19-negative relapse xenograft model, we determined that CART123, but not CART19, recognized leukemic blasts, established protracted synapses, and eradicated CD19-negative leukemia, leading to prolonged survival. Furthermore, combining CART19 and CART123 prevented antigen-loss relapses in xenograft models. Finally, we devised a dual CAR-expressing construct that combined CD19- and CD123-mediated T cell activation and demonstrated that it provides superior in vivo activity against B-ALL compared with single-expressing CART or pooled combination CART. In conclusion, these findings indicate that targeting CD19 and CD123 on leukemic blasts represents an effective strategy for treating and preventing antigen-loss relapses occurring after CD19-directed therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationCD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
Self-citationMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Self-citationKloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
Fielding, A. K., Richards, S. M., Chopra, R., Lazarus, H. M., Litzow, M. R., Buck, G., Durrant, I. J., Luger, S. M., Marks, D. I., Franklin, I. M., et al. (2007) · Blood · doi:10.1182/blood-2006-05-018192 · Cited by 841
Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C.-H., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 840
Jordan, C., Upchurch, D., Szilvassy, S., Guzman, M., Howard, D., Pettigrew, A., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401903 · Cited by 821
Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia
Mullighan, C. G., Phillips, L. A., Su, X., Ma, J., Miller, C. B., Shurtleff, S. A., & Downing, J. R. (2008) · Science · doi:10.1126/science.1164266 · Cited by 806
Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 735
Topp, M. S., Gökbuget, N., Zugmaier, G., Klappers, P., Stelljes, M., Neumann, S., Viardot, A., Marks, R., Diedrich, H., Faul, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.3247 · Cited by 658
Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C., & Chen, Y. Y. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0231 · Cited by 607
Soverini, S., Hochhaus, A., Nicolini, F. E., Gruber, F., Lange, T., Saglio, G., Pane, F., Müller, M. C., Ernst, T., Rosti, G., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326405 · Cited by 589
Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation
Vago, L., Perna, S. K., Zanussi, M., Mazzi, B., Barlassina, C., Stanghellini, M. T. L., Perrelli, N. F., Cosentino, C., Torri, F., Angius, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0811036 · Cited by 529
Generalized Lévy walks and the role of chemokines in migration of effector CD8+ T cells
Harris, T. H., Banigan, E. J., Christian, D. A., Konradt, C., Tait Wojno, E. D., Norose, K., Wilson, E. H., John, B., Weninger, W., Luster, A. D., et al. (2012) · Nature · doi:10.1038/nature11098 · Cited by 512
Self-citationGill, S., Tasian, S. K., Ruella, M., Shestova, O., Li, Y., Porter, D. L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S. A., et al. (2014) · Blood · doi:10.1182/blood-2013-09-529537 · Cited by 489
Self-citationModern Therapy of Acute Lymphoblastic Leukemia
Bassan, R., & Hoelzer, D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1382 · Cited by 485
Wilkie, S., van Schalkwyk, M. C. I., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9689-9 · Cited by 478
Topp, M. S., Gökbuget, N., Zugmaier, G., Degenhard, E., Goebeler, M.-E., Klinger, M., Neumann, S. A., Horst, H. A., Raff, T., Viardot, A., et al. (2012) · Blood · doi:10.1182/blood-2012-07-441030 · Cited by 474
Kenderian, S. S., Ruella, M., Shestova, O., Klichinsky, M., Aikawa, V, Morrissette, J. J. D., Scholler, J., Song, D., Porter, D. L., Carroll, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.52 · Cited by 426
Self-citationRelapsed childhood acute lymphoblastic leukaemia
Bhojwani, D., & Pui, C.-H. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70580-6 · Cited by 414
Mardiros, A., Dos Santos, C., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., Hoffman, L., Aguilar, B., Chang, W.-C., Bretzlaff, W., et al. (2013) · Blood · doi:10.1182/blood-2012-12-474056 · Cited by 374
Hegde, M., Corder, A., Chow, K. K., Mukherjee, M., Ashoori, A., Kew, Y., Zhang, Y. J., Baskin, D. S., Merchant, F. A., Brawley, V. S., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.185 · Cited by 373
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia
Castor, A., Nilsson, L., Åstrand-Grundström, I., Buitenhuis, M., Ramirez, C., Anderson, K., Strömbeck, B., Garwicz, S., Békássy, A. N., Schmiegelow, K., et al. (2005) · Nature Medicine · doi:10.1038/nm1253 · Cited by 334
Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D., Sandaltzopoulos, R., June, C. H., & Powell, D. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0008 · Cited by 329
Self-citationGenomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia
Mullighan, C. G., Phillips, L. A., Su, X., Ma, J., Miller, C. B., & Downing, J. R. (2008) · Blood · doi:10.1182/blood.v112.11.429.429 · Cited by 309
Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies.
Muñoz, L., Nomdedeu, J. F., López, O., Carnicer, M. J., Bellido, M., Aventin, A. M., Brunet, S., & Sierra, J. (2001) · PubMed · Cited by 269
Tavernier, E., Boiron, J.-M., Huguet, F., Bradstock, K., Vey, N., Kovacsovics, T., Delannoy, A., Fegueux, N., Fenaux, P., Stamatoullas, A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404824 · Cited by 256
Characterization of acute lymphoblastic leukemia progenitor cells
Cox, C. V., Evely, R. S., Oakhill, A., Pamphilon, D. H., Goulden, N. J., & Blair, A. (2004) · Blood · doi:10.1182/blood-2004-03-0901 · Cited by 246
Ruella, M., Kenderian, S. S., Shestova, O., Fraietta, J. A., Qayyum, S., Zhang, Q., Maus, M. V., Liu, X., Nunez-Cruz, S., Klichinsky, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1527 · Cited by 188
Self-citationChichili, G. R., Huang, L., Li, H., Burke, S., He, L., Tang, Q., Jin, L., Gorlatov, S., Ciccarone, V., Chen, F., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5693 · Cited by 172
Adoptive immunotherapy for cancer
Ruella, M., & Kalos, M. D. (2013) · Immunological Reviews · doi:10.1111/imr.12136 · Cited by 167
Self-citationGrupp, S. A., Maude, S. L., Shaw, P. A., Aplenc, R., Barrett, D. M., Callahan, C. A., Lacey, S. F., Levine, B. L., Melenhorst, J. J., Motley, L. S., et al. (2015) · Blood · doi:10.1182/blood.v126.23.681.681 · Cited by 140
Self-citationKügler, M., Stein, C., Kellner, C., Mentz, K., Saul, D., Schwenkert, M., Schubert, I. A., Singer, H., Oduncu, F. S., Stockmeyer, B., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08300.x · Cited by 137
He, S., Busfield, S. J., Ritchie, D. S., Hertzberg, M., Durrant, S., Lewis, I. D., Marlton, P. V., McLachlan, A. J., Kerridge, I., Bradstock, K. F., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.956316 · Cited by 130
Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells
Anurathapan, U., Chan, R. C., Hindi, H. F., Mucharla, R., Bajgain, P., Hayes, B. C., Fisher, W. E., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.262 · Cited by 128
CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis
Chung, E. Y., Psathas, J. N., Yu, D., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45851 · Cited by 94
CD123 and its potential clinical application in leukemias
Liu, K., Zhu, M., Huang, Y., Wei, S., Xie, J., & Xiao, Y. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.10.013 · Cited by 76
Mechanisms of resistance to FLT3 inhibitors
Chu, S. H., & Small, D. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2008.12.001 · Cited by 66
Leukemia Stem Cells and Human Acute Lymphoblastic Leukemia
Bernt, K. M., & Armstrong, S. A. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.09.010 · Cited by 60
Barrett, D. M., Seif, A. E., Carpenito, C., Teachey, D. T., Fish, J. D., June, C. H., Grupp, S. A., & Reid, G. S. D. (2011) · Blood · doi:10.1182/blood-2011-04-346528 · Cited by 56
Self-citationKuo, S.-R., Wong, L., & Liu, J.-S. (2012) · Protein Engineering Design and Selection · doi:10.1093/protein/gzs040 · Cited by 48
Ruella, M., & Gill, S. I. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1009888 · Cited by 32
Self-citationZereshkian, A., Leyton, J. V., Cai, Z., Bergstrom, D., Weinfeld, M., & Reilly, R. M. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.02.003 · Cited by 30
Fan, D., Li, Z., Zhang, X., Yang, Y., Yuan, X., Zhang, X., Yang, M., Zhang, Y., & Xiong, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0109-5 · Cited by 27
Tettamanti, S., Magnani, C. F., Biondi, A., & Biagi, E. (2013) · Immunology Letters · doi:10.1016/j.imlet.2013.09.013 · Cited by 21
Riccioni, R., Rossini, A., Calabrò, L., Diverio, D., Pasquini, L., Lo‐Coco, F., Peschle, C., & Testa, U. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/104281090310001646031 · Cited by 19
Cited by
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Tumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,183
Mechanisms of resistance to CAR T cell therapy
Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 959
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Cho, J. H., Collins, J. J., & Wong, W. W. (2018) · Cell · doi:10.1016/j.cell.2018.03.038 · Cited by 682
Metadata
- Authors
- Ruella, M., Barrett, D. M., Kenderian, S. S., Shestova, O., Hofmann, T. J., Perazzelli, J., Klichinsky, M., Aikawa, V., Nazimuddin, F., Kozlowski, M., Scholler, J., Lacey, S. F., Melenhorst, J. J., Morrissette, J. J. D., Christian, D. A., Hunter, C. A., Kalos, M., Porter, D. L., June, C. H., Grupp, S. A., & Gill, S.
- Venue
- Journal of Clinical Investigation
- Published
- 2016-08-29
- Volume
- 126
- Issue
- 10
- Pages
- 3814-3826
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2514418134
- Cited by
- 558
- References
- 51
- FWCI
- 28.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.